Loading…
Lobbying Spend
—
Filings
13
Firms Hired
1
Active Period
2020–2023
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Sickle Cell Care Expansion Act of 2022
2023 · first_quarter · Firm: ARTEMIS POLICY GROUP LLC
Health disparities as they relate to sickle cell disease Issues related to sickle cell disease and sickle cell trait Reintroduction of The Sickle Cell Care Expansion Act (H.R. 7177/S.4425) Healthcare issues related to hematologic diseases
Client expense: — · Firm income: $15,000
Matched citations: H.R. 7177
Sickle Cell Care Expansion Act of 2022
2023 · first_quarter · Firm: ARTEMIS POLICY GROUP LLC
Health disparities as they relate to sickle cell disease Issues related to sickle cell disease and sickle cell trait Reintroduction of The Sickle Cell Care Expansion Act (H.R. 7177/S.4425) Healthcare issues related to hematologic diseases
Client expense: — · Firm income: $15,000
Matched citations: S.4425
Consolidated Appropriations Act, 2023
2022 · fourth_quarter · Firm: ARTEMIS POLICY GROUP LLC
S.3389/ H.R.6216 - Sickle Cell Disease Comprehensive Care Act H.R. 2617 - Consolidated Appropriations Act of 2023 - Medicare provisions to eliminate cuts in physician payment and Medicaid provisions related to inclusion of S.3389/HR 6216. Making permanent Medicare telehealth expansions allowed during Public Health Emergency Legislation to eliminate CMS planned reductions to Medicare Physician Fee Schedule Conversion Factor and other payment reductions in Medicare proposed for 2022 The Improving Access to Transfusion Care for Hospice Patients Act of 2021 (S. 2566) Need for expert panel to advise CMS on improving values for evaluation and management services National Coverage Determination on myelodysplastic syndromes (MDS) Request for a Center for Medicare and Medicaid Innovation demonstration program for sickle cell disease
Client expense: — · Firm income: $45,000
Matched citations: H.R. 2617
Consolidated Appropriations Act, 2023
2022 · fourth_quarter · Firm: ARTEMIS POLICY GROUP LLC
H.R. 2617 - Consolidated Appropriations Act of 2023 - NIH and funding of CDC sickle cell data collection program FY 2023 House and Senate Labor HHS Appropriations bills Funding for CDC Sickle Cell Disease Data Collection Program and HRSA Sickle Cell Disease Regional Demonstration Program Funding for Hematology research and NIH total funding
Client expense: — · Firm income: $45,000
Matched citations: H.R. 2617
Health disparities as they relate to sickle cell disease Issues related to sickle cell disease and sickle cell trait The Sickle Cell Disease Treatment Centers Act (HR 8855/S 4866) 2022 Sickle Cell Disease Awareness Month Resolution The Sickle Cell Care Expansion Act (H.R. 7177/S.4425) Healthcare issues related to hematologic diseases CURES 2.0 draft legislation (H.R. 6000) Implementation of No Surprises Act
Client expense: — · Firm income: $45,000
Matched citations: H.R. 6000
Sickle Cell Disease Comprehensive Care Act
2022 · fourth_quarter · Firm: ARTEMIS POLICY GROUP LLC
S.3389/ H.R.6216 - Sickle Cell Disease Comprehensive Care Act H.R. 2617 - Consolidated Appropriations Act of 2023 - Medicare provisions to eliminate cuts in physician payment and Medicaid provisions related to inclusion of S.3389/HR 6216. Making permanent Medicare telehealth expansions allowed during Public Health Emergency Legislation to eliminate CMS planned reductions to Medicare Physician Fee Schedule Conversion Factor and other payment reductions in Medicare proposed for 2022 The Improving Access to Transfusion Care for Hospice Patients Act of 2021 (S. 2566) Need for expert panel to advise CMS on improving values for evaluation and management services National Coverage Determination on myelodysplastic syndromes (MDS) Request for a Center for Medicare and Medicaid Innovation demonstration program for sickle cell disease
Client expense: — · Firm income: $45,000
Matched citations: H.R.6216, HR 6216
Sickle Cell Care Expansion Act of 2022
2022 · fourth_quarter · Firm: ARTEMIS POLICY GROUP LLC
Health disparities as they relate to sickle cell disease Issues related to sickle cell disease and sickle cell trait The Sickle Cell Disease Treatment Centers Act (HR 8855/S 4866) 2022 Sickle Cell Disease Awareness Month Resolution The Sickle Cell Care Expansion Act (H.R. 7177/S.4425) Healthcare issues related to hematologic diseases CURES 2.0 draft legislation (H.R. 6000) Implementation of No Surprises Act
Client expense: — · Firm income: $45,000
Matched citations: H.R. 7177
Sickle Cell Disease Treatment Centers Act of 2022
2022 · fourth_quarter · Firm: ARTEMIS POLICY GROUP LLC
Health disparities as they relate to sickle cell disease Issues related to sickle cell disease and sickle cell trait The Sickle Cell Disease Treatment Centers Act (HR 8855/S 4866) 2022 Sickle Cell Disease Awareness Month Resolution The Sickle Cell Care Expansion Act (H.R. 7177/S.4425) Healthcare issues related to hematologic diseases CURES 2.0 draft legislation (H.R. 6000) Implementation of No Surprises Act
Client expense: — · Firm income: $45,000
Matched citations: HR 8855
Improving Access to Transfusion Care for Hospice Patients Act of 2021
2022 · fourth_quarter · Firm: ARTEMIS POLICY GROUP LLC
S.3389/ H.R.6216 - Sickle Cell Disease Comprehensive Care Act H.R. 2617 - Consolidated Appropriations Act of 2023 - Medicare provisions to eliminate cuts in physician payment and Medicaid provisions related to inclusion of S.3389/HR 6216. Making permanent Medicare telehealth expansions allowed during Public Health Emergency Legislation to eliminate CMS planned reductions to Medicare Physician Fee Schedule Conversion Factor and other payment reductions in Medicare proposed for 2022 The Improving Access to Transfusion Care for Hospice Patients Act of 2021 (S. 2566) Need for expert panel to advise CMS on improving values for evaluation and management services National Coverage Determination on myelodysplastic syndromes (MDS) Request for a Center for Medicare and Medicaid Innovation demonstration program for sickle cell disease
Client expense: — · Firm income: $45,000
Matched citations: S. 2566
Sickle Cell Disease Comprehensive Care Act
2022 · fourth_quarter · Firm: ARTEMIS POLICY GROUP LLC
S.3389/ H.R.6216 - Sickle Cell Disease Comprehensive Care Act H.R. 2617 - Consolidated Appropriations Act of 2023 - Medicare provisions to eliminate cuts in physician payment and Medicaid provisions related to inclusion of S.3389/HR 6216. Making permanent Medicare telehealth expansions allowed during Public Health Emergency Legislation to eliminate CMS planned reductions to Medicare Physician Fee Schedule Conversion Factor and other payment reductions in Medicare proposed for 2022 The Improving Access to Transfusion Care for Hospice Patients Act of 2021 (S. 2566) Need for expert panel to advise CMS on improving values for evaluation and management services National Coverage Determination on myelodysplastic syndromes (MDS) Request for a Center for Medicare and Medicaid Innovation demonstration program for sickle cell disease
Client expense: — · Firm income: $45,000
Matched citations: S.3389
Sickle Cell Care Expansion Act of 2022
2022 · fourth_quarter · Firm: ARTEMIS POLICY GROUP LLC
Health disparities as they relate to sickle cell disease Issues related to sickle cell disease and sickle cell trait The Sickle Cell Disease Treatment Centers Act (HR 8855/S 4866) 2022 Sickle Cell Disease Awareness Month Resolution The Sickle Cell Care Expansion Act (H.R. 7177/S.4425) Healthcare issues related to hematologic diseases CURES 2.0 draft legislation (H.R. 6000) Implementation of No Surprises Act
Client expense: — · Firm income: $45,000
Matched citations: S.4425
Sickle Cell Disease Treatment Centers Act of 2022
2022 · fourth_quarter · Firm: ARTEMIS POLICY GROUP LLC
Health disparities as they relate to sickle cell disease Issues related to sickle cell disease and sickle cell trait The Sickle Cell Disease Treatment Centers Act (HR 8855/S 4866) 2022 Sickle Cell Disease Awareness Month Resolution The Sickle Cell Care Expansion Act (H.R. 7177/S.4425) Healthcare issues related to hematologic diseases CURES 2.0 draft legislation (H.R. 6000) Implementation of No Surprises Act
Client expense: — · Firm income: $45,000
Matched citations: S 4866
Health disparities as they relate to sickle cell disease Issues related to sickle cell disease and sickle cell trait The Sickle Cell Disease Treatment Centers Act (HR 8855/S 4866) 2021 Sickle Cell Disease Awareness Month Resolution The Sickle Cell Care Expansion Act (H.R. 7177/S.4425) Healthcare issues related to hematologic diseases CURES 2.0 draft legislation (H.R. 6000) Implementation of No Surprises Act
Client expense: — · Firm income: $45,000
Matched citations: H.R. 6000
Sickle Cell Disease Comprehensive Care Act
2022 · third_quarter · Firm: ARTEMIS POLICY GROUP LLC
S.3389/ H.R.6216 - Sickle Cell Disease Comprehensive Care Act Making permanent Medicare telehealth expansions allowed during Public Health Emergency Legislation to eliminate CMS planned reductions to Medicare Physician Fee Schedule Conversion Factor and other payment reductions in Medicare proposed for 2022 The Improving Access to Transfusion Care for Hospice Patients Act of 2021 (S. 2566) Need for expert panel to advise CMS on improving values for evaluation and management services Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Proposed Policy Changes and Fiscal Year 2023 Rates Comments in response to CY2023 Medicare Physician Fee Schedule (CMS-1770-P) National Coverage Determination on myelodysplastic syndromes (MDS) Issues related to Medicare coverage of childhood vaccines for patients post-stem cell transplant
Client expense: — · Firm income: $45,000
Matched citations: H.R.6216
Sickle Cell Care Expansion Act of 2022
2022 · third_quarter · Firm: ARTEMIS POLICY GROUP LLC
Health disparities as they relate to sickle cell disease Issues related to sickle cell disease and sickle cell trait The Sickle Cell Disease Treatment Centers Act (HR 8855/S 4866) 2021 Sickle Cell Disease Awareness Month Resolution The Sickle Cell Care Expansion Act (H.R. 7177/S.4425) Healthcare issues related to hematologic diseases CURES 2.0 draft legislation (H.R. 6000) Implementation of No Surprises Act
Client expense: — · Firm income: $45,000
Matched citations: H.R. 7177
Sickle Cell Disease Treatment Centers Act of 2022
2022 · third_quarter · Firm: ARTEMIS POLICY GROUP LLC
Health disparities as they relate to sickle cell disease Issues related to sickle cell disease and sickle cell trait The Sickle Cell Disease Treatment Centers Act (HR 8855/S 4866) 2021 Sickle Cell Disease Awareness Month Resolution The Sickle Cell Care Expansion Act (H.R. 7177/S.4425) Healthcare issues related to hematologic diseases CURES 2.0 draft legislation (H.R. 6000) Implementation of No Surprises Act
Client expense: — · Firm income: $45,000
Matched citations: HR 8855
Improving Access to Transfusion Care for Hospice Patients Act of 2021
2022 · third_quarter · Firm: ARTEMIS POLICY GROUP LLC
S.3389/ H.R.6216 - Sickle Cell Disease Comprehensive Care Act Making permanent Medicare telehealth expansions allowed during Public Health Emergency Legislation to eliminate CMS planned reductions to Medicare Physician Fee Schedule Conversion Factor and other payment reductions in Medicare proposed for 2022 The Improving Access to Transfusion Care for Hospice Patients Act of 2021 (S. 2566) Need for expert panel to advise CMS on improving values for evaluation and management services Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Proposed Policy Changes and Fiscal Year 2023 Rates Comments in response to CY2023 Medicare Physician Fee Schedule (CMS-1770-P) National Coverage Determination on myelodysplastic syndromes (MDS) Issues related to Medicare coverage of childhood vaccines for patients post-stem cell transplant
Client expense: — · Firm income: $45,000
Matched citations: S. 2566
Sickle Cell Disease Comprehensive Care Act
2022 · third_quarter · Firm: ARTEMIS POLICY GROUP LLC
S.3389/ H.R.6216 - Sickle Cell Disease Comprehensive Care Act Making permanent Medicare telehealth expansions allowed during Public Health Emergency Legislation to eliminate CMS planned reductions to Medicare Physician Fee Schedule Conversion Factor and other payment reductions in Medicare proposed for 2022 The Improving Access to Transfusion Care for Hospice Patients Act of 2021 (S. 2566) Need for expert panel to advise CMS on improving values for evaluation and management services Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Proposed Policy Changes and Fiscal Year 2023 Rates Comments in response to CY2023 Medicare Physician Fee Schedule (CMS-1770-P) National Coverage Determination on myelodysplastic syndromes (MDS) Issues related to Medicare coverage of childhood vaccines for patients post-stem cell transplant
Client expense: — · Firm income: $45,000
Matched citations: S.3389
Sickle Cell Care Expansion Act of 2022
2022 · third_quarter · Firm: ARTEMIS POLICY GROUP LLC
Health disparities as they relate to sickle cell disease Issues related to sickle cell disease and sickle cell trait The Sickle Cell Disease Treatment Centers Act (HR 8855/S 4866) 2021 Sickle Cell Disease Awareness Month Resolution The Sickle Cell Care Expansion Act (H.R. 7177/S.4425) Healthcare issues related to hematologic diseases CURES 2.0 draft legislation (H.R. 6000) Implementation of No Surprises Act
Client expense: — · Firm income: $45,000
Matched citations: S.4425
Sickle Cell Disease Treatment Centers Act of 2022
2022 · third_quarter · Firm: ARTEMIS POLICY GROUP LLC
Health disparities as they relate to sickle cell disease Issues related to sickle cell disease and sickle cell trait The Sickle Cell Disease Treatment Centers Act (HR 8855/S 4866) 2021 Sickle Cell Disease Awareness Month Resolution The Sickle Cell Care Expansion Act (H.R. 7177/S.4425) Healthcare issues related to hematologic diseases CURES 2.0 draft legislation (H.R. 6000) Implementation of No Surprises Act
Client expense: — · Firm income: $45,000
Matched citations: S 4866
Health disparities as they relate to sickle cell disease Issues related to sickle cell disease and sickle cell trait Issues related to Sickle Cell Disease Treatment Centers 2021 Sickle Cell Disease Awareness Month Resolution The Sickle Cell Care Expansion Act (H.R. 7177/S.4425) Healthcare issues related to hematologic diseases CURES 2.0 draft legislation (H.R. 6000) Implementation of No Surprises Act Affordability of Employer Coverage for Family Members of Employees (REG-114339-21)
Client expense: — · Firm income: $45,000
Matched citations: H.R. 6000
Sickle Cell Disease Comprehensive Care Act
2022 · second_quarter · Firm: ARTEMIS POLICY GROUP LLC
S.3389/ H.R.6216 - Sickle Cell Disease Comprehensive Care Act Making permanent Medicare telehealth expansions allowed during Public Health Emergency Legislation to eliminate CMS planned reductions to Medicare Physician Fee Schedule Conversion Factor and other payment reductions in Medicare proposed for 2022 The Improving Access to Transfusion Care for Hospice Patients Act of 2021 (S. 2566) Need for expert panel to advise CMS on improving values for evaluation and management services National Coverage Determination on myelodysplastic syndromes (MDS) Issues related to Medicare coverage of childhood vaccines for patients post-stem cell transplant
Client expense: — · Firm income: $45,000
Matched citations: H.R.6216
Sickle Cell Care Expansion Act of 2022
2022 · second_quarter · Firm: ARTEMIS POLICY GROUP LLC
Health disparities as they relate to sickle cell disease Issues related to sickle cell disease and sickle cell trait Issues related to Sickle Cell Disease Treatment Centers 2021 Sickle Cell Disease Awareness Month Resolution The Sickle Cell Care Expansion Act (H.R. 7177/S.4425) Healthcare issues related to hematologic diseases CURES 2.0 draft legislation (H.R. 6000) Implementation of No Surprises Act Affordability of Employer Coverage for Family Members of Employees (REG-114339-21)
Client expense: — · Firm income: $45,000
Matched citations: H.R. 7177
Improving Access to Transfusion Care for Hospice Patients Act of 2021
2022 · second_quarter · Firm: ARTEMIS POLICY GROUP LLC
S.3389/ H.R.6216 - Sickle Cell Disease Comprehensive Care Act Making permanent Medicare telehealth expansions allowed during Public Health Emergency Legislation to eliminate CMS planned reductions to Medicare Physician Fee Schedule Conversion Factor and other payment reductions in Medicare proposed for 2022 The Improving Access to Transfusion Care for Hospice Patients Act of 2021 (S. 2566) Need for expert panel to advise CMS on improving values for evaluation and management services National Coverage Determination on myelodysplastic syndromes (MDS) Issues related to Medicare coverage of childhood vaccines for patients post-stem cell transplant
Client expense: — · Firm income: $45,000
Matched citations: S. 2566
Sickle Cell Disease Comprehensive Care Act
2022 · second_quarter · Firm: ARTEMIS POLICY GROUP LLC
S.3389/ H.R.6216 - Sickle Cell Disease Comprehensive Care Act Making permanent Medicare telehealth expansions allowed during Public Health Emergency Legislation to eliminate CMS planned reductions to Medicare Physician Fee Schedule Conversion Factor and other payment reductions in Medicare proposed for 2022 The Improving Access to Transfusion Care for Hospice Patients Act of 2021 (S. 2566) Need for expert panel to advise CMS on improving values for evaluation and management services National Coverage Determination on myelodysplastic syndromes (MDS) Issues related to Medicare coverage of childhood vaccines for patients post-stem cell transplant
Client expense: — · Firm income: $45,000
Matched citations: S.3389
Source: Senate LDA